US › Healthcare

Aprea Therapeutics Inc (APRE)

US · Healthcare · Biotechnology

$0.60+0.27%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.3M
Profit YoY
+16.4%
EPS
$-0.22
EPS estimate
$-0.23

EPS came in at -0.22 against a street estimate of -0.23 — a beat of 4.3%.

Key statistics

Market cap
$7.7M
Forward P/E
0.0
P/B
0.18
Book value
$3.47
EPS (TTM)
$-1.49
52-week high
$1.83
52-week low
$0.55
50-day MA
$0.75
200-day MA
$0.90
Beta
1.59

Analyst view

Analysts rate Aprea Therapeutics Inc a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $4.30.

Shareholding

Insiders
13.46%
Institutions
18.13%

Largest institutional holders

FundStake
AIGH Capital Management, LLC8.20%
Vestal Point Capital LP2.83%
Sphera Funds Management Ltd.2.18%
Nantahala Capital Management, LLC1.66%
Geode Capital Management, LLC0.96%
Scientech Research LLC0.49%
BNP Paribas Arbitrage, SA0.32%
Vanguard Fiduciary Trust Co0.31%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aprea Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.